Attention Deficits with or without Hyperactivity disorder (ADHD) is among the most prevalent childhood disorders, affecting approximately 5% of school-aged children. The average age of onset is 7 years old and symptoms can continue through adolescence and adulthood. It is a chronic, debilitating disorder, which impacts upon many aspects of an individual’s life, including academic difficulties, social skills problems and strained parent-child relationships. ADHD is a heterogeneous behavioral syndrome characterized by the core symptoms of hyperactivity, impulsivity and inattention. While these symptoms tend to cluster together, some people are predominantly hyperactive and impulsive, while others are principally inattentive.

Nowadays, primary treatments for ADHD include medication, cognitive-behavioral treatments and/or parent training. The use of psychostimulant as part of the pharmacological treatments demonstrated positive effects on ADHD symptoms, yielding to improved performance and functioning across multiple aspects of the disorder. However, medication also shows some limits among which a limited preservation of the effects after the end of the treatment.

 

As part of the clinical trial, the efficacy of the ADHD@Home solution developed by Mensia will be compared tothe efficacy of psychostimulant treatment such as Methylphenidate.